At the Trans-Pacific Partnership (TPP) negotiations in Atlanta, the US Trade Representative (USTR) is pushing the same harmful pharmaceutical proposal that many countries have rejected as recently as August – but wrapped in different packaging, according to US consumer advocacy Public Citizen.
The tactic is designed to break negotiators’ impasse over biotech drugs. The TPP talks in Maui (Hawaii) collapsed a month ago when trade ministers sparred over several issues including biologics exclusivity. But the US proposal would give pharmaceutical companies additional monopoly protections at the expense of public budgets and people’s health, Public Citizen said yesterday.
The USTR has long pushed for increased marketing exclusivity periods for biologics – medical products derived from living organisms, including many new and forthcoming cancer treatments. Exclusivity means product monopolies, with no competition from generics or biosimilars; medicine prices in the tens and hundreds of thousands of dollars per person; and the rationing of treatment access.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze